Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641007 | 1.00 | OPRM1 (0.43) | OPRM1OPRL1SLC6A2GRIN1GRIN2A | |
| SCHEMBL13640927 | 0.87 | TNKS (0.37) | OPRM1OPRL1SLC6A2GRIN1GRIN2A | |
| SCHEMBL13641059 | 0.87 | OPRM1 (0.43) | OPRM1OPRL1LRRK2OPRK1 | |
| SCHEMBL13640923 | 0.84 | TNKS (0.41) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL13644097 | 0.79 | OPRL1 (0.43) | OPRM1OPRL1SLC6A2GRIN1GRIN2A | |
| SCHEMBL12899071 | 0.78 | OPRM1 (0.45) | OPRM1OPRL1SLC6A2GRIN1GRIN2A | |
| SCHEMBL12084100 | 0.77 | OPRM1 (0.46) | OPRM1OPRL1SLC6A2GRIN1GRIN2A | |
| SCHEMBL13640808 | 0.76 | OPRM1 (0.54) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL12293656 | 0.76 | OPRM1 (0.54) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL13644039 | 0.75 | OPRM1 (0.41) | OPRM1OPRL1SLC6A2GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | OPRM1 177/4885OPRL1 108/4885SLC6A2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.